Cargando…

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data

SIMPLE SUMMARY: Management of malignant pleural mesothelioma (MPM) is challenging as patients frequently present with unresectable disease and the response rates with systemic therapy alone remain low. Given the paucity of effective therapies for MPM, Tumor Treating Fields (TTFields) therapy was mad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kutuk, Tugce, Appel, Haley, Avendano, Maria Carolina, Albrecht, Federico, Kaywin, Paul, Ramos, Suyen, Suarez-Murias, Melanie E., Mehta, Minesh P., Kotecha, Rupesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032984/ https://www.ncbi.nlm.nih.gov/pubmed/35454925 http://dx.doi.org/10.3390/cancers14082020

Ejemplares similares

Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Evaluating the intracranial activity of adagrasib
por: Kotecha, Rupesh, et al.
Publicado: (2023)

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
por: Barbier, Michaela Carla, et al.
Publicado: (2023)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

SPIN-01 RADIATION THERAPY ALONE VERSUS RADIATION THERAPY PLUS RADIOFREQUENCY ABLATION/VERTEBRAL AUGMENTATION FOR SPINE METASTASIS: TRIAL IN PROGRESS
por: Kotecha, Rupesh, et al.
Publicado: (2022)

Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma
por: Kutuk, Tugce, et al.
Publicado: (2023)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
por: Røe, Oluf Dimitri, et al.
Publicado: (2012)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
por: Kotecha, Rupesh, et al.
Publicado: (2021)

Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results
por: Kutuk, Tugce, et al.
Publicado: (2022)

Zero Setup Margin Mask versus Frame Immobilization during Gamma Knife(®) Icon™ Stereotactic Radiosurgery for Brain Metastases
por: Kutuk, Tugce, et al.
Publicado: (2022)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
por: Ponce, Santiago, et al.
Publicado: (2023)

33. SYSTEMATIC REVIEW AND META-ANALYSIS OF BREAST CANCER BRAIN METASTASIS AND PRIMARY TUMOR RECEPTOR EXPRESSION DISCORDANCE
por: Kotecha, Rupesh, et al.
Publicado: (2020)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
por: Bellini, Alice, et al.
Publicado: (2021)

Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance
por: Kotecha, Rupesh, et al.
Publicado: (2021)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
por: Federico, Rea, et al.
Publicado: (2013)

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
por: Wu, Mindan, et al.
Publicado: (2023)

Prognostic and predictive role of [(18)F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
por: Zucali, Paolo Andrea, et al.
Publicado: (2017)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy
por: Saint-Pierre, Mathieu D., et al.
Publicado: (2015)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

Editorial: Effects of radiation therapies on brain metastases
por: Kotecha, Rupesh, et al.
Publicado: (2023)

RONC-08. SURVIVAL IMPACT OF POSTOPERATIVE RADIOTHERAPY TIMING IN PEDIATRIC AND YOUNG ADULT EPENDYMOMA
por: Shah, Sunny, et al.
Publicado: (2020)

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
por: Sun, Rong, et al.
Publicado: (2022)

Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
por: Seifi, Sharareh, et al.
Publicado: (2023)

Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial
por: Kotecha, Rupesh, et al.
Publicado: (2020)

Dosimetric Impact of Lesion Number, Size, and Volume on Mean Brain Dose with Stereotactic Radiosurgery for Multiple Brain Metastases
por: La Rosa, Alonso, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_95vnm3ae8gqdhpo1nikt3aatjj